Cell-mediated and humoral immunity of choroidal melanoma patients after treatment with photocoagulation combined with strontium-90/yttrium-90 therapy versus transpupillary thermotherapy combined with strontium-90/yttrium-90 therapy

Authors

  • D.A. Drumi SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"
  • S.I. Poliakova SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"
  • L.M. Velychko SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"
  • M.B. Makarova SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"
  • I.V. Tsukanova SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"
  • O.V. Bogdanova SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"

DOI:

https://doi.org/10.31288/oftalmolzh202513440

Keywords:

choroidal melanoma, transpupillary thermotherapy, photocoagulation, brachytherapy, immunology, oncology, radiology

Abstract

Purpose: To compare cell-mediated and humoral immunity characteristics of patients with T1 to T3 CM treated with photocoagulation (PC) combined with strontium-90 (Sr90)/ yttrium-90 (Yt90) brachytherapy (BT)) versus transpupillary thermotherapy (TTT) combined with Sr90/Yt90 BT.

Material and Methods: Eighty-seven patients with T1 to T3 CM were included in the study. Group 1 (TTT plus BT) included 31 patients, group 2 (PC plus BT) included 56 patients, and the control group included 44 healthy individuals. Groups were comparable in terms of age, gender and tumor location.

Results: The following parameters were significantly increased (р < 0.009) in group 1 compared to controls and group 2: leukocytes (by 1.1 thousand cell/µl and 1.3 thousand cell/µl, respectively), absolute counts and percentages of lymphocytes (by 0.6 thousand cell/µl and 1.0 thousand cell/µl, and by 5.5% and 10.3%, respectively), absolute counts of CD3+ T cells (by 376.2 thousand cell/µl and 520.0 thousand cell/µl, respectively), CD4+ T helpers (by 351.2 thousand cell/µl and 362.0 thousand cell/µl, respectively), CD8+ T suppressors (by 125.8 thousand cell/µl and 133.8 thousand cell/µl, respectively). In addition, there was an increase in absolute counts and percentage of phagocytic neutrophils (by 953.0 thousand cell/µl and 18.5%, respectively) compared to controls, absolute counts of СD16+ NK cells compared to controls and group 2 (by 88.5 thousand cell/µl and 119.2 thousand cell/µl, respectively), absolute counts of СD19+ B cells compared to group 2 (by 166.7 thousand cell/µl) and absolute counts of IgA compared to controls (by 0.5 g/l) and IgM compared to controls and group 2 (by 0.4 g/l and 0.7 g/l, respectively). Moreover, the CD4+/CD8+ ratio was by 2.2 increased compared to controls and by 1.0 decreased compared to group 2. In group 1, there was a decrease in the percentages of CD3+ (by 13.3%) and CD4+ (by 14.5%) compared to group 2, and absolute counts of IgG (by 2.0 g/l) compared to controls. The only substantial changes in immunological parameters with treatment were an increase in the percentage of NK cells by 4.3% (р = 0.02) in group 1 and a reduction in the percentage of phagocytic neutrophils by 15.8% (р = 0.0000) and an increase in IgM by 0.2 g/l (р = 0.002) in group 2.

Conclusion: We found that, at baseline, patients with T1 to T3 CM had an active immune response to tumor antigens. In addition, they exhibited no statistically significant changes in the parameters of cell-mediated and humoral immunity after treatment with TTT (delivered using the developed methodology) combined with Sr90/Yt90 BT, excepting an increase in the percentage of NK cells by 4.3% (р = 0.02).

Author Biographies

D.A. Drumi , SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"

Drumi D. A., Post-Graduate Student and Ophthalmologist, Ocular Oncology Microsurgery Department, SI “The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine”, Odesa (Ukraine)

S.I. Poliakova , SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"

Poliakova S. I., Senior Researcher, Dr Sc (Med), Ocular Oncology Microsurgery Department, SI “The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine”, Odesa (Ukraine)

L.M. Velychko , SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"

Velychko L. M., Dr Sc (Med), Head of Immunology Laboratory, SI “The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine”, Odesa (Ukraine)

M.B. Makarova , SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"

Makarova M. B., Cand Sc (Med), Head of Clinical Laboratory, SI “The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine”, Odesa (Ukraine)

I.V. Tsukanova , SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"

Tsukanova I. V., Junior Researcher, Cand Sc (Med), Ocular Oncology Microsurgery Department, SI “The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine”, Odesa (Ukraine)

O.V. Bogdanova , SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"

Bogdanova O. V., Cand Sc (Biol), Immunology Laboratory, SI “The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine”, Odesa (Ukraine)

References

Chandran SS, Somerville RPT, Yang JC, et al. Treatment of metastatic uveal melanoma with adoptive transfer of tumor-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncol. 2017;2045(17):1-11. https://doi.org/10.1016/S1470-2045(17)30251-6

Reiman A, Kikuchi H, Scocchia D, et al. Validation of an NGS mutation detection panel for melanoma. BMC Cancer. 2017;17(1):150. https://doi.org/10.1186/s12885-017-3149-0

Velychko LM. [Immune correction with alfa-2beta interferon for optimized treatment for uveal melanoma]. Abstract of Cand Sc (Med) Thesis. Kyiv; 2000. Ukrainian.

Velychko LM. [Immunopathogenetic mechanisms of tumor process progression and their correction during eye-preserving treatment for uveal melanoma]. Abstract of Dr Sc (Med) Dissertation. Odesa: Filatov Institute of Eye Disease; 2018. Ukrainian.

Maletskyi AP. [Efficacy of organ-saving treatment of uveal melanoma patients depending on clinical and morphological characteristics of the tumor and body resistance to the tumor]. Abstract of Dr Sc (Med) Dissertation. Odesa: Filatov Institute of Eye Disease; 2001. Ukrainian.

Poliakova SI, Velichko LM, Bogdanova AV, Tsukanova IV. Natural antitumor resistance of the organism condition of patients with uveal melanoma of small sizes. J Ophthalmol (Ukraine). 2016;1:27-30. https://doi.org/10.31288/oftalmolzh201612730

Blank C, Kuball J, Voelkl S, et al. Blokade of PD-L1 (B7-H1) augments human tumor-spescific T cell responses in vitro. Int.J.Cancer. 2006;119:317-327. https://doi.org/10.1002/ijc.21775

Mantovani A, Germano G, Marchesi F, et al. Cancer-promoting tumor-associated macrophages: new vistas and open questions. Eur. J. Immunol. 2011; 41:2522-2525. https://doi.org/10.1002/eji.201141894

Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008; 454:436-444. https://doi.org/10.1038/nature07205

Singh AD, Aronow ME, Sun Y, et al. Chromosome 3 status in uveal melanoma: a comparison of fluorescence in situ hybridization and single-nucleotide polymorphism array. Invest. Ophthalmol. Vis. Sci. 2012;53(7):3331-3339. https://doi.org/10.1167/iovs.11-9027

Fridman WH, Galon J, Pages F, et al. Prognostic and predictive impact of intra and peritumoral immune infiltrates. Cancer Res. 2011;71(17):5601-5605. https://doi.org/10.1158/0008-5472.CAN-11-1316

Verma V, Mehta MP. Clinical outcomes of proton radiotherapy for uveal melenoma. Cham: Springer International Publishing; 2016. https://doi.org/10.1016/j.clon.2016.01.034

Burgmans MC, de Leede EM, Martini CH, Kapiteijn E, Vahrmeijer AL, van Erkel AR. Percutaneous isolated hepatic perfusion for the treatment of unresectable liver malignancies. Cardiovasc Intervent Radiol. 2016;39(6):801-814. https://doi.org/10.1007/s00270-015-1276-z

Reddy SK, Kesmodel SB, Alexander HR. Isolated hepatic perfusion for patients with liver metastases. Ther Adv Med Oncol. 2014;6(4):180-194. https://doi.org/10.1177/1758834014529175

Hughes MS, Zager J, Faries M, et al. Results of a randomized controlled multicenter phase III tial of percutaneous hepatic perfusion compared with best available care for patients with melanoma liver metastases. Ann Surg Oncol. 2016;23(4):1309-1319. https://doi.org/10.1245/s10434-015-4968-3

Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539-545. https://doi.org/10.1016/S0140-6736(00)04046-0

Tsukanova IV. [Efficacy of modified transpupillary thermotherapy in the treatment for Т1N0M0 choroidal melanoma]. Abstract of Cand Sc (Med) Thesis. Odesa, Filatov Institute of Eye Diseases and Tissue Therapy; 2021. Ukrainian.

Male D, Brostoff J, Roth D, Roitt I, editors. [Immunology]. Logosfera: Moscow; 2007. Russian.

Vanechkin, Bushuieva NM, Degtiarenko TV, Usov NI. [Guidelines on prompt primary assessment of the immune status]. Odesa;1990. Russian.

Degtiarenko TV, Bushuieva NM, Usov NI. [Guidelines on prompt primary assessment of the immune status]. Odesa; 1999. Russian.

Moreno PMD, Pago AP. Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic. Front Chem 2014;2(October):1-7. https://doi.org/10.3389/fchem.2014.00087

Khvorova A, Watts JK. The chemical evolution of oligonucleotide therapies of clenical utility. Nat Biotechnol. 2017;35(3):238-248. https://doi.org/10.1038/nbt.3765

Posch C, Latorre A, Crosby MB et al. Detection of GNAQ mutations and reduction of cell viability in uveal melanoma cells with functionalized gold nanoparticles. Biomed Microdevices 2015;17(1):15. https://doi.org/10.1007/s10544-014-9908-7

Chandran SS, Somerville RPT, Yang JC, et al. Tretment of metastatic uveal melanoma wiyh adoptive transfer of tumour-infiltrating, lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncol. 2017;2045(17):1-11. https://doi.org/10.1016/S1470-2045(17)30251-6

Reiman A, Kikuchi H, Scocchia D, et al. Validation of an NGS mutation detection panel for melanoma. BMC Cancer. 2017;17(1):150. https://doi.org/10.1186/s12885-017-3149-0

Oliva M, Rullan AJ, Piulats JM, Uveal melanoma as a target for immune-therapy. Ann Transl Med. 2016;4(9):172-172. https://doi.org/10.21037/atm.2016.05.04

Downloads

Published

2025-03-03

How to Cite

1.
Drumi D, Poliakova S, Velychko L, Makarova M, Tsukanova I, Bogdanova O. Cell-mediated and humoral immunity of choroidal melanoma patients after treatment with photocoagulation combined with strontium-90/yttrium-90 therapy versus transpupillary thermotherapy combined with strontium-90/yttrium-90 therapy. J.ophthalmol. (Ukraine) [Internet]. 2025 Mar. 3 [cited 2025 Mar. 9];(1):34-40. Available from: http://ua.ozhurnal.com/index.php/files/article/view/257

Issue

No. 1 (2025): Journal of Ophthalmology (Ukraine)

Section

Clinical Ophthalmology

License

Copyright (c) 2025 Drumi D. A., Poliakova S. I. , Velychko L. M., Tsukanova I. V., Makarova M. B., Bogdanova O. V.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.

COPYRIGHT NOTICE

Authors who publish in this journal agree to the following terms:

  1. Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
  2. The copyright commencement date complies the publication date of the issue, where the article is included in.

DEPOSIT POLICY

  1. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
  3. Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
  4. Archiving the pre-print (pre-refereeing manuscript version) not allowed.

Most read articles by the same author(s)